ANGIOMAX

This brand name is authorized in United States. It is also authorized in Australia, New Zealand.

Active ingredients

The drug ANGIOMAX contains one active pharmaceutical ingredient (API):

1	Bivalirudin UNII TN9BEX005G - BIVALIRUDIN
	Bivalirudin is a direct and specific thrombin inhibitor that binds both to the catalytic site and the anion-binding exosite of fluid-phase and clot-bound thrombin.
	Read more about Bivalirudin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ANGIOMAX Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B01AE06	Bivalirudin	B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AE Direct thrombin inhibitors
Discover more medicines within B01AE06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8844L
CA	Health Products and Food Branch	02246533
NZ	Medicines and Medical Devices Safety Authority	8383, 9424
US	FDA, National Drug Code	0781-3447, 65293-001, 70511-141